Asahi Kasei has unveiled plans to acquire Aicuris in a deal worth 780 million euros ($920 million), marking the latest in a ...

After promising to sell off 7% of its business back in November, Charles River Laboratories has delivered. | After promising to sell off 7% of its business back in November, Charles River Laboratories ...

In an effort to battle against what members feel is an existential threat to their business, a group of 10 domestic biotech companies have launched the Midsized Biotech Alliance of America with a ...

The federal government is pledging as much as $144 million to anti-aging research over the next five years through the Advanced Research Projects Agency for Health (ARPA-H), a subject area previously ...

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as ...

When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...

With its cash cache set to run out by the fourth quarter of this year, Werewolf Therapeutics is prowling the biotech landscape for a deal to keep its pipeline afloat. | With its cash cache set to run ...

Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion. | Harbour BioMed is setting sail as the Solstice begins, ...

The FDA has ordered MacroGenics to halt enrollment in a phase 2 trial of the biotech’s lead candidate lorigerlimab following severe side effects that led to one patient's death.

Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by deploying Evinova’s AI-native platform in an effort to speed up clinical development.

Less than a year after announcing the spinout of its diabetes division, Medtronic says it is seeking $784 million in an initial public offering for the MiniMed business. | Less than a year after ...